Plain-English translation of NCT05520788 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study helps doctors find the right cancer medication for you by first testing your tumor's genes. If your genetic test shows a specific mutation that can be treated with an FDA-approved drug, you'll receive that targeted medication. The research team will then monitor how well the treatment works and how safe it is for your body.
Not all cancer drugs work the same way for every patient. By matching the medication to your tumor's unique genetic profile, doctors hope to improve survival rates and reduce unnecessary side effects in people with advanced liver and bile duct cancer.
You likely qualify if…
You likely don't qualify if…
First, you'll have a genetic test (next-generation sequencing) to analyze your tumor's DNA and find targetable mutations. If a match is found, you'll start taking the personalized medication and have regular follow-up visits to check how well it's working, measure any side effects, and monitor your overall health. The study will continue to track your progress until the end of the trial or as long as the medication is helping you.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China
Sponsor
Tongji Hospital
Enrollment target
~200 participants
Started
May 2020
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Bixiang Zhang, PhD
Tongji Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.